MedTrace Logo

Study of [3H] BMS747158 in Healthy Male Subjects

NCT00930631 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2020-11-10

No results posted yet for this study

Summary

The purpose of this clinical study is to assess the safety, extent and route of \[3H\] BMS747158 radioactivity eliminated (mass balance) in urine and feces of healthy male subjects. The safety of \[3H\] BMS747158 administration will also be assessed, as well as pharmacokinetics of \[3H\] BMS747158 and metabolite identification.

Conditions

Interventions

DRUG

[3H] BMS747158

Single bolus intravenous injection of \[3H\] BMS747158

Sponsors & Collaborators

  • Lantheus Medical Imaging

    lead INDUSTRY

Principal Investigators

  • Debra A Mandarino, MD · Covance Clinical Laboratory Unit

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2009-07-31
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00930631 on ClinicalTrials.gov